Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of huperzine A in the preparation of medicines for treating glaucoma and/or ischemia-induced optic nerve damage

A technology for optic nerve damage, huperzine A, applied in the field of medicine

Inactive Publication Date: 2011-11-30
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no literature report that huperzine A can play a role in the treatment of glaucoma through its cholinergic and non-cholinergic protective effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of huperzine A in the preparation of medicines for treating glaucoma and/or ischemia-induced optic nerve damage
  • Use of huperzine A in the preparation of medicines for treating glaucoma and/or ischemia-induced optic nerve damage
  • Use of huperzine A in the preparation of medicines for treating glaucoma and/or ischemia-induced optic nerve damage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: The intraocular pressure-lowering effect of huperzine A on rats with chronic glaucoma

[0025] Purpose and principle: To induce chronic glaucoma rat model by ligation of scleral vein. Electrocoagulation of the scleral vein causes the formation of aqueous humor to be blocked, forming a chronic high intraocular pressure model, simulating the damage of glaucomatous high intraocular pressure to nerve cells such as the optic nerve head. This model can be used to evaluate the intraocular pressure-lowering effect and retinal optic nerve protection effect of anti-glaucoma drugs.

[0026] Methods: Rats were anesthetized by intravenous injection of pentobarbital sodium 30 mg / kg, fixed on the experimental operating table, the upper and lower eyelids were threaded for traction, and the cornea and conjunctiva of the operated eye was anesthetized with 1% tetracaine, and the upper corneoscleral limbus was anesthetized. Cut the bulbar conjunctiva, bluntly dissect the fascia...

Embodiment 2

[0029] Example 2: Miotic and intraocular pressure-lowering effects of huperzine A on chronic glaucoma rabbit model

[0030] Purpose and principle: To induce a rabbit model of chronic glaucoma by injection of α-chymotrypsin. Induced by injecting α-chymotrypsin into the posterior chamber of the rabbit eye, α-chymotrypsin hydrolyzes the crystal zonules to form fragments that block the trabecular meshwork, resulting in the formation of aqueous humor and obstruction of discharge, resulting in high intraocular pressure. This model can be used to evaluate the miotic and intraocular pressure-lowering effects of anti-glaucoma drugs, as well as the protective effect of retinal optic nerve.

[0031] Methods: Rabbit ocular hypertension model, anesthetized, miotic constriction, injection needle inserted through the pupil into the posterior chamber to inject 0.2ml of 500U / ml α-chymotrypsin, the needle tip swings to facilitate the even distribution of α-chymotrypsin in the posterior chamber,...

Embodiment 3

[0034] Example 3: Protective effect of huperzine A on retinal damage in rats induced by ischemia or ocular hypertension

[0035] Purpose and principle: Using pressurized perfusion to induce acute glaucoma model in rats or bilateral common carotid artery ligation-induced global cerebral ischemia model, using crystal violet (Cresyl Violet acetate) and HE method to detect retinal ganglion damage and huperzine A protective effect. The acute glaucoma model forms a high intraocular pressure model in a short period of time. The high intraocular pressure compresses the optic nerve and creates a pressure injury model in a short period of time, simulating retinal ischemia during acute glaucoma attacks, causing damage to the retina and optic nerve. Bilateral cervical conjunctivitis induces global cerebral ischemia, including retinal ischemia, in rats.

[0036] method:

[0037] Rat model of glaucoma induced by pressurized perfusion: SD rats were anesthetized with 30 mg / kg pentobarbita...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medical technology, and relates to the effective monomer component of lycopodium alkaloids isolated from Chinese folk herbal medicine Huperzia Serrata - huperzine A ((-)-huperzineA) in the preparation of treatment of glaucoma and / or Or use in medicine for ischemia-induced optic nerve damage. The structural formula of the compound huperzine A involved in the present invention is as follows. Experiments have confirmed that huperzine A has significant miotic effect and intraocular pressure-lowering effect on glaucoma animal models, and has obvious protective effects on retinopathy and apoptosis inflammatory protein expression in animals induced by ischemia or high intraocular pressure. Developed as a new drug for the treatment of glaucoma and / or ischemia-induced optic nerve damage. Huperzine A (-)-Huperzine A.

Description

technical field [0001] The invention relates to the field of medical technology, and relates to the effective monomer component of lycopodium alkaloids isolated from Chinese folk herbal medicine Huperzia Serrata - huperzine A ((-)-huperzineA) in the preparation of treatment of glaucoma and / or Or use in medicine for ischemia-induced optic nerve damage. Background technique [0002] Glaucoma is a clinically common eye disease, the main symptoms of which are progressive optic nerve damage and visual field defect caused by elevated intraocular pressure, which can eventually lead to blindness. The main means of treating glaucoma are medicine, laser and surgery, among which the control of intraocular pressure with medicine is the most important and basic means of treatment, which has an irreplaceable role. Now there are many drugs for glaucoma, including cholinergic drugs, adrenergic receptor blockers, prostaglandins and so on. Cholinemimetic drugs mainly by enhancing cholinergi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4748A61P27/06A61P27/02
Inventor 章海燕甘勇何伟唐希灿甘莉王维张馨欣危军臧广喜
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com